Production (Stage)
Fate Therapeutics, Inc.
FATE
$1.28
-$0.125-8.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 7.46% | -15.74% | -2.92% | 16.94% | 19.10% |
| Total Depreciation and Amortization | -7.60% | 3.72% | 4.36% | 14.83% | 24.52% |
| Total Amortization of Deferred Charges | -- | -- | -100.00% | -100.00% | -100.00% |
| Total Other Non-Cash Items | 60.86% | 389.99% | 308.22% | 551.56% | 169.50% |
| Change in Net Operating Assets | -203.94% | -110.21% | 53.81% | -370.28% | 166.86% |
| Cash from Operations | 9.81% | 7.10% | 22.98% | 25.15% | 35.63% |
| Capital Expenditure | 39.29% | 88.14% | 93.57% | 95.75% | 89.44% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -68.13% | -89.10% | -73.27% | -82.22% | -41.61% |
| Cash from Investing | -68.85% | -89.16% | -71.14% | -80.63% | -34.12% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | 28,387.55% | 4,136.36% | 2,209.33% | 1,041.76% |
| Repurchase of Common Stock | -270.00% | -270.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -74.64% | -- | -- | -- | -- |
| Cash from Financing | -95.38% | 117,420.00% | 5,319.87% | 2,854.48% | 1,341.23% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -202.65% | 44.84% | 99.23% | -15.98% | 448.81% |